Novo CEO Doustdar 'Very Optimistic' About CagriSema

Novo Nordisk CEO Mike Doustdar said the company expects FDA approval for the obesity drug CagriSema by the end of 2026 and a launch in early 2027. Doustdar made the statement on Bloomberg Television after Novo raised its annual forecast. The company's weight-loss drugs Ozempic and Wegovy contributed to the earnings increase that prompted the revised forecast.

• Bloomberg — Novo CEO Doustdar 'Very Optimistic' About CagriSema

Next story